Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) concerning whether a series of statements by ACADIA Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On April 9, 2018, a report by CNN revealed that “physicians, medical researchers and other experts told CNN that they worried that Nuplazid had been approved too quickly, based on too little evidence that it was safe or effective.”

Following this news, NASDAQ: ACAD fell more than 23% on April 9, 2018.

On April 10, 2018, the Food and Drug Administration revealed it would continue to monitor reports of adverse events.

On July 9, 2018, The Southern Investigative Reporting Foundation published a report claiming that ACADIA’s “pursuit of regulatory approval is best described as ‘loophole-centric’.”

Based in San Diego, California, and founded in 1993 ACADIA Pharmaceuticals Inc focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.

If you purchased shares of ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) on or before April 9, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185